Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.

Gasparyan, Armen Yuri; Kitas, George D

Gasparyan, Armen Yuri; Kitas, George D.

Gasparyan AY; Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom.
Kitas GD; Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, United Kingdom.

Mediterr J Rheumatol ; 33(2): 173-175, 2022 Jun.

Article in English | MEDLINE | ID: covidwho-1988963

Keywords

COVID-19; anakinra; canakinumab; cytokine release syndrome; hereditary autoinflammatory diseases; interleukin-1; interleukin-6

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Mediterr J Rheumatol Year: 2022 Document Type: Article Affiliation country: Mjr.33.2.173

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google